Pharmaron Beijing Co., Ltd.
300759
주식 순위
#2354
Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a... Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Manufacturing Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy Services; and Others. The company offers laboratory chemistry and biological science services, including small molecule chemical drugs, oligonucleotides, peptides, antibodies, antimicrobial agents, antibody-drug conjugates (ADCs), and cell and gene therapy products; small molecule CDMO services, such as API process development and production, material science and preformulation, formulation development, and analytical development. It also provides clinical research services; macromolecular and cell and gene therapy services comprising drug discovery, development and production services, cell and gene therapy laboratory services, and gene therapy drug development and production services. In addition, the company is involved in the provision of technology development, technology transfer, technical consultation, technical services, and technical training; import and export of goods and technologies. Pharmaron Beijing Co., Ltd. was incorporated in 2004 and is headquartered in Beijing, the People's Republic of China.
주가
$5.58
시가총액
$8.24B
변동 (1일)
-3.77%
변동 (1년)
28.36%
국가
CN
거래 Pharmaron Beijing Co., Ltd. (300759)
카테고리
Healthcare
Pharmaron Beijing Co., Ltd. (300759)의 발행 주식 수
June 2026 기준 발행 주식 수: 1.84B
Pharmaron Beijing Co., Ltd.의 최신 재무 보고서와 주가에 따르면 현재 발행 주식 수는 1.84B입니다. December 2024 말 기준 회사는 1.77B주를 발행했습니다. 발행 주식 수는 일반적으로 주식 분할이나 자사주 매입에 의해 영향을 받습니다.
Pharmaron Beijing Co., Ltd. (300759)의 발행 주식 수 기록 (2014 ~ 2026)
매년 말 기준 발행 주식 수
| 연도 | 발행 주식 수 | 변화 |
|---|---|---|
| 2026 (TTM) | 1.84B | 4.27% |
| 2025 | 1.76B | -0.44% |
| 2024 | 1.77B | -0.31% |
| 2023 | 1.78B | 0.12% |
| 2022 | 1.77B | 124.21% |
| 2021 | 790.81M | 0.07% |
| 2020 | 790.22M | 20.39% |
| 2019 | 656.41M | 7.15% |
| 2018 | 612.62M | -31.00% |
| 2017 | 887.91M | 17.11% |
| 2016 | 758.19M | 50.00% |
| 2015 | 505.46M | 0.00% |
| 2014 | 505.46M | 0.00% |
유사 기업 또는 경쟁사의 발행 주식 수
| 회사 | 발행 주식 수 | 차이 | 국가 |
|---|---|---|---|
| 253.90M | -86.18% |
US
|
|
| 396.00M | -78.45% |
US
|
|
| 478.91M | -73.93% |
AU
|
|
| 0.00 | -100.00% |
BE
|
|
| 62.19M | -96.62% |
NL
|
